Clinical trials: Idiopathic Polypoidal Choroidal Vasculopathy
- Condition Idiopathic Polypoidal Choroidal Vasculopathy
- Funder type Industry (pharma, biotech, devices)
Idiopathic Polypoidal Choroidal Vasculopathy
A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
The objectives of this study are to evaluate the safety and tolerability of Zimura™ intravitreous injection in combination with anti-vascular endothelial growth factor (VEGF) therapy in subjects with Idiopathic Polypoidal…
- Trial name
- NCT02397954
- Testing
- Avacincaptad Pegol
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Ophthotech Corporation
Idiopathic Polypoidal Choroidal Vasculopathy
ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
To asses the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Eylea® in treatment experienced subjects with idiopathic polypoidal choroidal vasculopathy
- Trial name
- NCT03374670
- Testing
- Zimura, Eylea
- Where
- United States
- Sponsor
- Ophthotech Corporation